UNDERSTANDING ANTITUMOR T CELL IMMUNITY IN HIGH-RISK LOCALIZED PROSTATE CANCER AFTER NEOADJUVANT TREATMENT WITH AN ANTIBODY TARGETING THE B7-H3 CHECKPOINT
$1,220,281FY2019Defense Health AgencyDOD
The Johns Hopkins University
The Johns Hopkins University